The European Medicines Agency’s safety committee “has not yet reached a conclusion and the review is currently ongoing”, the Amsterdam-based EMA said in a statement to Agence France-Presse.
“We will communicate and hold a press briefing as soon as the review is finalized. This is currently expected tomorrow (Wednesday, 7 April) or on Thursday, 8 April,” it added.
The statement came after the EMA’s head of vaccine strategy Marco Cavaleri was quoted in Italian media as saying that there was a “clear” connection, and that the agency would announce it within hours.
“In my opinion, we can say it now, it is clear there is a link with the vaccine. But we still do not know what causes this reaction,” Cavaleri told Italy’s Il Messaggero newspaper in an interview.
After several countries suspended the use of the AstraZeneca jab, the EMA said on March 18 that the benefits of using it outweigh the risks and it should remain in use.
But it has said there is a possible link to rare blood clots and that it would issue updated advice during this week’s meeting of its safety committee.
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.